In Vivo Cellular and Molecular Imaging Center@Stanford

斯坦福体内细胞和分子成像中心

• 批准号: 8726913
• 负责人: SANJIV S GAMBHIR
• 金额: $ 192.69万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-01 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8726913
• 关键词: Animals; Applications Grants; Automobile Driving; Biomedical Engineering; Cancer Patient; Chemistry; Child; Clinical; Commit; Development; Discipline; Ensure; Enzymes; Excision; Faculty; Funding; Goals; Grant; Image; Immunology; In Vitro; Individual; Investments; Leadership; Life; Magnetic Resonance Imaging; Malignant Neoplasms; Medical; Medical Oncology; Microbiology; Molecular; Monitor; Non-Small-Cell Lung Carcinoma; Outcome; Pediatrics; Pharmacology; Physicians; Physics; Positron-Emission Tomography; Postdoctoral Fellow; Radiochemistry; Radiology Specialty; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Science; Scientist; Structure; TNFRSF5 gene; Training; Training Programs; Translations; Universities; Work; anticancer research; cancer therapy; career; flexibility; improved; in vivo Cellular and Molecular Imaging Centers; mathematical model; medulloblastoma; molecular imaging; multimodality; nanodiagnostic; next generation; professor; programs; response

DESCRIPTION (provided by applicant): The Molecular Imaging Program at Stanford (MIPS) is an inter-departmental program with the goal of advancing multimodality molecular imaging of living subjects with a particular focus on cancer. A renewal application (for years 6-10) for an in vivo cellular and molecular imaging center at Stanford (ICMIC@Stanford) P50 is now proposed. This proposal will allow continued momentum for the MIPS with a particular emphasis on clinical translation. Through significant continued investments by Stanford University in new research and clinical translational space, infrastructure, and new faculty recruitments, the MIPS are continuing to rapidly expand. Dr. Sam Gambhir, Professor of Radiology and Bioengineering, Director of MIPS, will continue to work closely with Dr. Christopher Contag, Associate Professor of Pediatrics, and Co-Director of the MIPS. Together, Drs. Gambhir (PI for this grant application) and Contag (Co-PI) form a unique leadership team that spans the breadth of disciplines involved in multimodality molecular imaging. The goal of the ICMIC@Stanford proposal is to develop state-of-the-art molecular imaging strategies for enabling cancer research and clinical translation for improved patient cancer management. Four research projects and four developmental projects spanning different components of molecular imaging research are the main science driving this grant. Two of the four research projects have specific clinical translational components that focus on predicting and monitoring response to non-small cell lung cancer (NSCLC) therapy using in vitro nano-diagnostics and molecular imaging with PET. One of the four research projects validates image-guided resection to improve outcomes for children with medulloblastoma. Another research project develops new strategies for enzyme-activated PET and MRI imaging agents. The research involves both physicians and scientists to better facilitate clinical translation. The ICMIC@Stanford investigators are from a variety of disciplines and expertise including Medical Oncology, Radiochemistry, Chemistry, Radiology, Microbiology & Immunology, Medical Physics, Bioengineering, Molecular Pharmacology and Mathematical Modeling. Three specialized resources including 1- Chemistry/Radiochemistry, 2- Small Animal Imaging, and 3- Imaging Quantitation and Analysis will help ensure that the ICMIC@Stanford grant functions efficiently. Finally, a structured training program with 2 post-docs funded by the ICMIC@Stanford with flexibility to train individuals at different career levels will ensure the ability to train next-generation interdisciplinary leaders in molecular imaging. The ICMIC@Stanford team is committed to cancer research and clinical translation of state-of-the-art molecular imaging strategies for improving clinical cancer management.

描述（由申请人提供）：斯坦福大学的分子成像程序（MIPS）是一个部门间计划，其目的是推进对生命受试者的多模式分子成像，特别关注癌症。现在提出了斯坦福（ICMIC@stanford）P50的体内细胞和分子成像中心的续订应用（6 - 10年）。该建议将允许MIP的持续势头，并特别强调临床翻译。通过斯坦福大学在新的研究和临床转化领域，基础设施和新教师招聘方面的持续投资，MIP正在继续迅速扩展。放射学和生物工程教授，MIPS主任Sam Gambhir博士将继续与儿科副教授Christopher Contag博士和MIPS联合主任紧密合作。在一起，博士。 Gambhir（此赠款申请的PI）和Contag（Co-Pi）组成了一个独特的领导团队，涵盖了多模式分子成像所涉及的学科的广度。 ICMIC@Stanford提案的目的是制定最先进的分子成像策略，以实现癌症研究和临床翻译，以改善患者癌症的管理。四个研究项目和四个涵盖分子成像研究不同组成部分的发展项目是推动这笔赠款的主要科学。这四个研究项目中的两个具有特定的临床翻译成分，这些成分侧重于预测和监测对非小细胞肺癌（NSCLC）治疗的反应，并使用PET进行体外纳米诊断和分子成像。四个研究项目之一验证了图像引导的切除，以改善髓母细胞瘤儿童的预后。另一项研究项目开发了用于酶激活PET和MRI成像剂的新策略。该研究涉及医生和科学家，以更好地促进临床翻译。 ICMIC@Stanford研究人员来自各种学科和专业知识，包括医学肿瘤学，放射化学，化学，放射学，微生物学和免疫学，医学物理学，生物工程，分子药理学和数学建模。三个专业资源，包括1-化学/放射化学，2-小动物成像以及3个成像定量和分析，将有助于确保ICMIC@Stanford Grant有效地发挥作用。最后，一个结构化的培训计划，由ICMIC@Stanford资助的2个后DOC，灵活地培训不同职业水平的个人，将确保能够培训下一代跨学科领导者的分子成像。 ICMIC@Stanford团队致力于改善临床癌症管理的最先进分子成像策略的癌症研究和临床翻译。

项目成果

Family of enhanced photoacoustic imaging agents for high-sensitivity and multiplexing studies in living mice.

用于活体小鼠高灵敏度和多重研究的增强型光声成像剂系列。

• DOI: 10.1021/nn204352r
• 发表时间: 2012-06-26
• 期刊: ACS nano
• 影响因子: 17.1
• 作者: de la Zerda A;Bodapati S;Teed R;May SY;Tabakman SM;Liu Z;Khuri-Yakub BT;Chen X;Dai H;Gambhir SS
• 通讯作者: Gambhir SS

Single-Cell Analysis of [18F]Fluorodeoxyglucose Uptake by Droplet Radiofluidics.

• DOI: 10.1021/acs.analchem.5b00792
• 发表时间: 2015-07-07
• 期刊: Analytical chemistry
• 影响因子: 7.4
• 作者: Türkcan S;Nguyen J;Vilalta M;Shen B;Chin FT;Pratx G;Abbyad P
• 通讯作者: Abbyad P

Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging.

• DOI: 10.1002/stem.81
• 发表时间: 2009-07
• 期刊: STEM CELLS
• 影响因子: 5.2
• 作者: Wang, Hui;Cao, Feng;De, Abhijit;Cao, Yuan;Contag, Christopher;Gambhir, Sanjiv S.;Wu, Joseph C.;Chen, Xiaoyuan
• 通讯作者: Chen, Xiaoyuan

[(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography.

• DOI: 10.1039/c6cc00895j
• 发表时间: 2016-04-07
• 期刊: Chemical communications (Cambridge, England)
• 作者: Carroll VN;Truillet C;Shen B;Flavell RR;Shao X;Evans MJ;VanBrocklin HF;Scott PJ;Chin FT;Wilson DM
• 通讯作者: Wilson DM

Theranostic mesoporous silica nanoparticles biodegrade after pro-survival drug delivery and ultrasound/magnetic resonance imaging of stem cells.

• DOI: 10.7150/thno.11389
• 发表时间: 2015
• 期刊: Theranostics
• 影响因子: 12.4
• 作者: Kempen PJ;Greasley S;Parker KA;Campbell JL;Chang HY;Jones JR;Sinclair R;Gambhir SS;Jokerst JV
• 通讯作者: Jokerst JV